The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
This study is a pilot, randomized, placebo-controlled, single-center study of Fisetin in
elderly nursing home participants with non-, mildly-, or moderately-symptomatic and confirmed
SARS-CoV-2 infection.
Drug: Fisetin
~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 & 1 and Days 8 & 9)
Other Name: 3,3',4',7-tetrahydroxyflavone
Drug: Placebo
Placebo looks exactly like the treatment drug, but it contains no active ingredient
Inclusion Criteria:
1. Men or post-menopausal women age ≥65 years.
2. Current nursing home resident.
3. CoV severity of moderate or less OR SpO2 ≥ 85% (on room air or ≤ 2 L of supplemental
oxygen at time of enrollment.
4. SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic or other CLIA certified
laboratory within 10 days before randomization.
5. Willing and able to provide written informed consent or have a legally authorized
representative (LAR) who will provide informed consent.
Exclusion Criteria:
1. Presence of any condition that the Investigator or the subject's attending physician,
physician's assistant, or nurse-practitioner believes would put the subject at risk or
would preclude the patient from successfully completing the trial.
2. Pregnancy (note that only post-menopausal women will be enrolled).
3. Total bilirubin >3X upper limit of normal or as per clinical judgment.
4. Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) >4x the upper
limits of normal or as per clinical judgment.
5. Hemoglobin <7 g/dL; white blood cell count ≤2,000/mm3 (≤2.0 x 109/L) or ≥25,000/mm3
(≥25 x 109/L); platelet count ≤ 40,000/μL (≤40 x 109/L); absolute neutrophil count ≤1
x 109/L; lymphocyte count <0.3 x 109/L at screening or as per clinical judgment.
6. Unstable (as per clinical judgment) major cardiovascular, renal, endocrine,
immunological, or hepatic disorder.
7. eGFR <25 ml/ min/ 1.73 m2 or as per clinical judgment.
8. Plasma and/or serum glucose >300 or as per clinical judgment.
9. Human immunodeficiency virus infection.
10. Known active hepatitis B or C infection.
11. Invasive fungal infection.
12. Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites.
13. New/active invasive cancer except non-melanoma skin cancers as per clinical judgment.
14. Known condition associated with major immunodeficiency as per clinical judgment.
15. Known hypersensitivity or allergy to Fisetin.
16. Subjects taking any of the medications listed in Protocol Appendix 1 may participate
if they are otherwise eligible AND the medication can be safely held during the
following times:
- Immediately before the 1st IP administration (Day 0) until at least 10 hours
after the 2nd IP administration (Day 1)
- Immediately before the 3rd IP administration (Day 8) until at least 10 hours
after the 4th IP administration (Day 9)
17. Participation in other clinical trials involving treatment for COVID-19. Note that
institutional standard of care treatment of COVID-19 including glucocorticoids,
hydroxychloroquine, azithromycin, remdesivir, anti-spike antibodies, and/or
convalescent plasma are not excluded from the study.
18. History of diverticulitis or diverticulosis with GI bleeding, as per clinical
judgment.
Mayo Clinic
Rochester, Minnesota, United States
James L Kirkland, MD, PhD, Principal Investigator
Mayo Clinic